Clinical trials: Glabellar Lines
Glabellar Lines
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines
- Trial name
- NCT07013279
- Testing
- DWP712 inj., Botox® 100 Units
- Where
- South Korea
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Frown Lines
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton).
- Trial name
- Head2Head (NCT00777803)
- Testing
- NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®)), OnabotulinumtoxinA (Vistabel®)
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 381 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Lines
To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.
To compare the safety and efficacy of "HG-102" with Botox® in the improvement of moderate to severe glabellar lines.
- Trial name
- NCT04944953
- Testing
- Botulinum Toxin Type A Injection [Botox], Botulinum toxin type A injection [HG-102]
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Hugel
Glabellar Lines
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.
- Trial name
- NCT06212960
- Testing
- DWP712, BOTOX®
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Lines
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05496335
- Testing
- AGN-151586, BOTOX
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- AbbVie
Glabellar Lines
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines.
- Trial name
- NCT00512135
- Testing
- IncobotulinumtoxinA (Xeomin) (20 units)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 801 people
- Sponsor
- Merz Pharmaceuticals GmbH
Frown Lines
Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
The purpose of the study is to provide preliminary comparative data on BoNT/A-DP versus Botox Cosmetic. Subsequently the sample size is primarily based on clinical judgement and practical considerations.
- Trial name
- H2H (NCT04763265)
- Testing
- Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 208 people
- Sponsor
- Croma-Pharma GmbH
Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, IncobotulinumtoxinA (Xeomin) causes local weakening.
- Trial name
- NCT00430963
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- Germany
- Volunteers
- 256 people
- Sponsor
- Merz Pharmaceuticals GmbH
Skin Aging
Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines
This study evaluates the patient satisfaction and onset of effect following treatment with botulinum toxin Type A in the treatment of glabellar rhytids (frown lines)
- Trial name
- NCT00856414
- Testing
- botulinum toxin Type A
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Allergan
Glabellar Frown Lines
Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
Non-interventional PASS of NUCEIVA for the treatment of moderate-to-severe glabellar lines to provide additional characterisation of the long-term safety of NUCEIVA in the real-world clinical practice setting.
- Trial name
- NCT05481931
- Testing
- prabotulinumtoxinA
- Where
- Germany
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Longitudinal Evaluation and Real-world Evidence of NT201
This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A…
- Trial name
- NCT05222607
- Testing
- IncobotulinumtoxinA
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Merz North America, Inc.
Glabellar Frown Lines
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to placebo in treatment of glabellar lines.
- Trial name
- NCT05217355
- Testing
- MBA-P01 (Botulinum toxin A)
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Medytox Korea
Glabellar Lines
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
The objective of this study is to demonstrate the efficacy of Dysport for the improvement in appearance of moderate to severe glabellar lines and to assess the short term and long term safety of Dysport, used for the improvement…
- Trial name
- NCT02450526
- Testing
- Botulinum toxin type A
- Where
- 10 sites in China
- Volunteers
- 520 people
- Sponsor
- Ipsen
Glabellar Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
- Trial name
- NCT03014622
- Testing
- Botulinum Toxins, Type A
- Where
- 15 sites in United States
- Volunteers
- 303 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT06205797
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Huons Biopharma
Moderate to Severe Glabellar Lines
DWP450 for Treating Moderate to Severe Glabellar Lines
A multi-center, randomized, double-blind, positive drug-controlled clinical study to evaluate the safety and efficacy of Botulinum Toxin Type A for Injection in the treatment of moderate to severe glabellar lines
- Trial name
- NCT06354127
- Testing
- DWP450, Botox®
- Where
- China
- Volunteers
- 473 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Frown Lines
Study Comparing Treatment With Alluzience vs Reconstituted Toxin
This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum…
- Trial name
- STAR (NCT05277337)
- Testing
- Alluzience, powder BoNT-A (BOTOX/Vistabel)
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Galderma R&D
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01224015
- Testing
- normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 684 people
- Sponsor
- Allergan
Upper Facial Lines, Glabellar Lines
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines.
- Trial name
- NCT07871513
- Testing
- TrenibotulinumtoxinE and OnabotulinumtoxinA, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- AbbVie
Glabellar Frown Lines
Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to BOTOX in treatment of glabellar lines.
- Trial name
- NCT05059587
- Testing
- MBA-P01, BOTOX
- Where
- South Korea
- Volunteers
- 318 people
- Sponsor
- Medytox Korea